Most GLP-1 providers advertise a starting price that hides the real maintenance-dose cost.
By the time patients reach a therapeutic maintenance dose — where the majority of meaningful weight loss occurs — the real monthly cost is often 50% to 100% higher than the homepage number. This guide ranks providers by their true all-in cost at maintenance dose, not their introductory rate.
Luma Health offers compounded semaglutide at $197/month flat and compounded tirzepatide at $297/month flat — no dose-tier increases, no contracts, no hidden fees. Clinical oversight by Wasef Health, PC. Pharmacy: VialsRX, 503A licensed, TX Board #35264.
If you have spent any time searching for GLP-1 medication online, you have almost certainly encountered a confusing range of prices. One platform advertises semaglutide starting at $69 per month. Another claims $149. A third shows $199 but insists that includes everything. Meanwhile, patients who have actually enrolled frequently report paying significantly more than the advertised rate by month three or four of treatment.
The reason for this gap is systematic: GLP-1 medications like semaglutide and tirzepatide are prescribed on a titration schedule. Patients begin at a low starting dose and increase every four weeks until reaching a therapeutic maintenance dose. Most providers price their medication by dose tier. The advertised starting price is almost always the cheapest tier. The price at the maintenance dose, where patients spend the vast majority of their treatment time, is considerably higher — and often not prominently disclosed.
This guide cuts through that confusion. We have analyzed the publicly disclosed pricing of the major GLP-1 telehealth providers, compared starting prices against maintenance-dose prices, factored in consultation fees, contract obligations, and shipping costs, and produced a ranking based on what patients actually pay over a realistic 12-month treatment course.
The cost that matters is where you spend most of your time
The landmark STEP 1 trial (Wilding et al., N Engl J Med 2021) demonstrated that meaningful weight loss with semaglutide — an average of 14.9% of body weight — was observed over 68 weeks at the 2.4 mg maintenance dose. SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022) showed tirzepatide achieving up to 22.5% body weight reduction at the 15 mg maintenance dose over 72 weeks.
In both trials, patients spent the first 16 to 20 weeks titrating upward and the remaining 48 to 52 weeks at or near the maintenance dose. For a patient on a 12-month program, the starting-dose price applies for roughly two to four months, while the maintenance-dose price applies for the remaining eight to ten months. Annual cost — not monthly starting price — is the number that matters.
GLP-1 Provider Price Rankings: 2026
The table below ranks nine major GLP-1 telehealth providers by estimated annual cost for semaglutide treatment, factoring in typical dose escalation over a 12-month course. Prices reflect published rates as of June 2026.
| # | Provider | Starting Price | Maintenance Price | Est. Annual Cost | Contract? |
|---|---|---|---|---|---|
| 1 | Luma Health | $197/mo | $197/mo (flat) | ~$2,364 | None |
| 2 | Henry Meds | ~$69/mo | ~$149–$199/mo | $1,800–$2,400 | Some plans |
| 3 | Hims | ~$79/mo | ~$149–$199/mo | $1,800–$2,400 | Some plans |
| 4 | Ro | ~$99/mo | ~$179–$249/mo | $2,100–$3,000 | Some plans |
| 5 | Found | ~$99/mo | ~$199–$299/mo | $2,400–$3,600 | Varies |
| 6 | Noom Med | ~$149/mo | ~$199–$299/mo | $2,400–$3,600 | Varies |
| 7 | Calibrate | ~$199/mo | ~$299–$399/mo | $3,600–$4,800 | 6–12 months |
| 8 | Sequence | ~$199/mo | ~$299–$399/mo | $3,600–$4,800 | Varies |
| 9 | LillyDirect (brand) | ~$349/mo | ~$349–$499/mo | $4,200–$6,000 | None |
All figures are estimates based on published pricing as of June 2026 and assume 12 months of treatment with standard dose escalation. Verify current rates directly with each provider before enrolling.
What These Rankings Actually Reveal
The most important insight from the table above is that providers advertising the lowest starting prices do not necessarily deliver the lowest total cost. A provider offering $69 per month as a starting rate but charging $199 at maintenance will cost a patient more over a 12-month treatment course than a provider offering a flat $197 rate from month one. The starting price is a marketing number. The maintenance price is the financial reality.
This pattern is not accidental. Low starting prices generate enrollment. Dose-dependent price increases, applied after patients have already begun treatment, established habits, and seen early results, create strong financial and psychological incentives to stay even as costs rise. Patients who have lost 8 to 12 pounds in their first two months are unlikely to shop around for a new provider when their price increases — which is precisely the dynamic that makes tiered pricing so effective as a business model.
A second pattern worth noting is the role of contract commitments. Providers that lock patients into 6 or 12-month contracts shift the financial risk entirely onto the patient. If the medication causes intolerable side effects, if the patient's health circumstances change, or if a lower-cost alternative becomes available, contracted patients face cancellation penalties or simply continue paying for a program that no longer serves them. No-contract providers preserve the patient's flexibility to adjust, pause, or switch without financial penalty.
Hidden Costs to Watch For
Even providers with transparent published pricing often have costs that are not immediately visible during the enrollment process. Understanding these categories in advance protects you from pricing surprises after you have committed to a program.
Separate Consultation Fees
Some platforms charge a one-time or recurring consultation fee billed separately from the medication cost. This can add $50 to $150 to your effective monthly cost and is often disclosed only in fine print during enrollment.
Dose-Escalation Price Jumps
The most common hidden cost. The advertised price applies to the starting dose only. At each dose increase — typically every 4 weeks — the monthly cost increases, sometimes significantly. Always ask for the full pricing schedule before enrolling.
Shipping and Handling Fees
Not all providers include shipping in their advertised price. Temperature-controlled packaging and multi-vial shipments may be charged separately. Over 12 months, shipping fees can add $100 to $300 to your total cost.
Contract Cancellation Penalties
Programs requiring 6 or 12-month commitments may charge cancellation fees or require you to pay out the remaining balance if you discontinue early. These can represent hundreds of dollars in financial exposure.
Platform or Membership Fees
Some programs charge a monthly platform or membership fee on top of medication costs — common in programs that bundle coaching, app access, or behavioral support. Evaluate whether those additional services are worth the premium.
Lab Work Requirements
Certain providers require baseline bloodwork or periodic labs as a condition of continued prescribing. If these are not included in the program cost, they can add $100 to $400 annually in out-of-pocket expenses.
Provider-by-Provider Breakdown
The summary table above gives a snapshot, but a closer look at each provider's program structure reveals important differences in what you are actually getting for the price.
How to Evaluate a GLP-1 Provider Beyond Price
Price is the most visible variable when comparing GLP-1 providers, but it is not the only variable that matters. Patients who choose the cheapest available option without evaluating clinical quality, pharmacy standards, and program support sometimes find that a marginally lower monthly cost comes with meaningful trade-offs in service quality, response time, and clinical oversight.
- Pharmacy accreditation: Compounded GLP-1 medications should be prepared by a 503A licensed sterile compounding pharmacy with a clean state pharmacy board record. Ask each provider for the name and license number of their compounding pharmacy and verify it directly through the relevant state pharmacy board. Luma Health uses VialsRX (Houston, TX, TX Board #35264), a licensed 503A pharmacy.
- Prescriber licensure: The clinician who reviews your intake and issues your prescription must be licensed in your state of residence. Verify that the platform uses US-licensed prescribers and that they conduct a genuine clinical review of your health history rather than rubber-stamping intake forms.
- Full pricing disclosure: Before enrolling, request the complete pricing schedule for all dose tiers, not just the starting price. A reputable provider should be able to tell you exactly what you will pay at each escalation step, including any additional fees for consultations, shipping, or labs.
- Clinical accessibility: Side effect management is an important part of GLP-1 treatment, particularly during the titration phase. Evaluate how quickly you can reach a clinical team member if you have questions about nausea, dose adjustments, or unexpected symptoms.
- Contract terms and cancellation policy: Read the contract before enrolling. Understand what happens if you want to pause, switch providers, or discontinue treatment. Providers with no-contract month-to-month plans offer more financial flexibility than those with 6 or 12-month commitments.
- Active ingredient disclosure: Reputable compounding pharmacies disclose the active ingredients and concentrations in their formulations. Be cautious of any provider that is vague about what is in their medication or that makes claims about proprietary blends without clinical justification.
Compounded vs. Brand-Name GLP-1: Cost and Quality Context
Nearly all of the lower-cost GLP-1 telehealth options in this ranking use compounded semaglutide or tirzepatide rather than the FDA-approved branded versions — Wegovy, Ozempic, Mounjaro, or Zepbound. Understanding the difference is important for making an informed decision.
Compounded GLP-1 medications are prepared by licensed 503A pharmacies using the same active pharmaceutical ingredient as the branded versions. They are not FDA-approved drug products in the same sense as branded medications — they are prepared per individual prescription and regulated at the state pharmacy board level. However, when prepared by a properly licensed pharmacy following USP standards, compounded medications use the same active ingredient and deliver it through the same mechanism of action.
The cost difference is substantial. Brand-name Wegovy (semaglutide 2.4 mg) has a list price of approximately $1,349 per month without insurance. Compounded semaglutide from licensed telehealth providers ranges from $150 to $300 per month at maintenance doses. For patients without insurance coverage, compounded options represent the only financially viable path to access. For a deeper comparison, see our guide on compounded semaglutide vs. Wegovy.
Flat-rate GLP-1 — no pricing surprises.
Compounded semaglutide $197/month. Compounded tirzepatide $297/month. Same price at every dose. No contracts. VialsRX pharmacy, TX Board #35264.
Start Your Intake →Frequently Asked Questions
Price differences between GLP-1 providers reflect a combination of factors: the cost structure of their compounding pharmacy partnerships, their marketing spend (which ultimately gets recovered through patient pricing), the level of clinical support included in the program, their profit margin targets, and the way they structure their pricing model — tiered versus flat. Providers that advertise very low starting prices typically recover their costs through dose-escalation pricing increases that patients encounter once they are already enrolled and invested in the program. True cost comparisons require looking at maintenance-dose pricing and annual cost, not the headline starting number.
Price alone does not determine safety. What determines safety is whether the compounding pharmacy is properly licensed and inspected, whether the medication is correctly formulated to USP standards, and whether there is adequate clinical oversight from a licensed prescriber who has actually reviewed your health history. A provider charging $150 per month using a properly licensed and inspected 503A pharmacy with attentive clinical support is safer than a provider charging $300 per month but cutting corners on pharmacy vetting or clinical review. Always verify pharmacy licensure independently — do not rely solely on the provider's assurances. For VialsRX, Luma Health's pharmacy, you can verify license #35264 directly at pharmacy.texas.gov.
Most telehealth providers offering compounded GLP-1 medications operate on a cash-pay model and do not bill insurance. Compounded medications are generally not covered by insurance even when the equivalent branded version is. Some platforms help patients access branded medications through insurance, but the compounded alternatives that make up the majority of the telehealth GLP-1 market are typically a direct patient expense. Brand-name Wegovy and Zepbound are covered by some employer-sponsored plans, but coverage varies enormously and prior authorization requirements are common. According to KFF's 2024 Employer Health Benefits Survey, approximately 19% of large employer plans cover GLP-1s for obesity — meaning the majority of patients are paying out of pocket.
For compounded GLP-1 treatment through telehealth providers, true annual costs range from approximately $1,800 to $4,800 depending on the provider, medication type, dose tier, and plan structure. Semaglutide programs generally cost less than tirzepatide programs at equivalent dose levels. The most cost-effective programs in this ranking deliver maintenance-dose treatment in the $2,000 to $2,500 annual range with no contracts or hidden fees. Branded medications from pharmacy chains without insurance cost $12,000 to $16,000 annually at list price — making them financially inaccessible for most patients without coverage.
Tirzepatide is consistently priced higher than semaglutide across all providers — typically $50 to $150 more per month at comparable dose tiers. This reflects the higher cost of the active pharmaceutical ingredient and the more complex manufacturing process. Clinically, tirzepatide is a dual GIP/GLP-1 receptor agonist while semaglutide is a pure GLP-1 receptor agonist, and trial data shows tirzepatide achieving modestly greater average weight loss at maximum doses. Whether the additional cost is justified depends on individual clinical circumstances — a question best answered in consultation with your prescribing provider. For a detailed clinical comparison, see our semaglutide vs. tirzepatide guide.
Verify the pharmacy's license number directly through the relevant state pharmacy board — do not rely on the provider's own assurances. For Texas pharmacies, the Texas State Board of Pharmacy maintains a public license verification database at pharmacy.texas.gov. For pharmacies in other states, the National Association of Boards of Pharmacy (NABP) provides a resource for locating state board verification tools. Additionally, look for pharmacies that operate under USP chapter 797 sterile compounding standards and can provide a certificate of analysis for their formulations upon request. A legitimate compounding pharmacy will disclose its license number and welcome verification.
Yes, with some practical considerations. GLP-1 medication is not bound to a specific provider — if you switch, your new provider will conduct an intake evaluation and issue a new prescription based on your current dose level. The main barriers to switching are contract commitments at providers with multi-month plans, and the brief interruption in medication delivery during the transition period. Patients on providers with no-contract month-to-month plans can switch at any time without penalty. Allow two to three weeks for your new provider to process your intake and ship your first order to minimize any gap in treatment.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Rubino DM, et al. Effect of Continued Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. PubMed 33755728
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA.gov — Wegovy PI
- U.S. FDA. Human Drug Compounding — Section 503A. FDA.gov — 503A Compounding
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
- KFF. 2024 Employer Health Benefits Survey. kff.org — 2024 Employer Survey